Shield Therapeutics (LON:STX) Stock Price Passes Below 50-Day Moving Average – Should You Sell?

Shield Therapeutics plc (LON:STX) passed below its 50-day moving average during trading on Friday . The stock has a 50-day moving average of GBX 10.65 and traded as low as GBX 10. Shield Therapeutics shares last traded at GBX 10.60, with a volume of 1,701,659 shares trading hands.

Wall Street Analyst Weigh In

Separately, Peel Hunt reissued a “buy” rating and set a GBX 15 target price on shares of Shield Therapeutics in a research note on Friday, November 7th. One equities research analyst has rated the stock with a Buy rating, According to data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of GBX 15.

Shield Therapeutics Price Performance

The stock’s 50-day moving average is GBX 10.65 and its 200 day moving average is GBX 8.45. The company has a debt-to-equity ratio of 3,691.50, a quick ratio of 2.16 and a current ratio of 1.05. The stock has a market capitalization of £113.21 million, a PE ratio of -5.30 and a beta of 1.42.

Shield Therapeutics Company Profile

Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S. with an exclusive, multi-year commercial agreement with Viatris Inc (Viatris). Outside of the U.S., the Company has licensed the rights to four specialty pharmaceutical companies.